Inocras Study Validates Whole-Genome HRD Scoring for Ovarian Cancer Treatment
Event summary
- Inocras' study, published at ASCO 2026, found whole-genome HRD phenotyping predicts PARP inhibitor benefit in first-line high-grade serous ovarian cancer.
- WGS-HRD-positive patients had a median progression-free survival (mPFS) of 27.5 months vs. 12.0 months for WGS-HRD-negative patients.
- 21.4% of patients were WGS-HRD positive despite lacking BRCA mutations, highlighting the method's additional diagnostic value.
- The study compared 84 patients using Inocras' CancerVision platform, showing superior predictive value over conventional scarHRD methods.
The big picture
Inocras' findings align with the growing trend of leveraging whole-genome sequencing for precision oncology, potentially reshaping how ovarian cancer patients are stratified for PARP inhibitor therapy. The study underscores the shift from BRCA-focused testing to more comprehensive genomic assessments, which could expand the addressable market for bioinformatics-driven diagnostics. The real-world evidence strengthens Inocras' position as a key player in the precision medicine space, particularly in oncology.
What we're watching
- Clinical Validation
- Whether prospective studies will confirm WGS-HRD's predictive value in broader patient populations.
- Market Adoption
- The pace at which oncologists integrate whole-genome HRD scoring into treatment decision-making.
- Competitive Positioning
- How Inocras differentiates CancerVision from existing genomic testing platforms.
Related topics